A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT ID: NCT03272503
Last Updated: 2020-05-28
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE2
Total Enrollment
100 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-10-27
Study Completion Date
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will look at whether Pimozide may help to slow the progression of Amyotrophic Lateral Sclerosis.
100 people from several Canadian centres with ALS who have provided their consent will be randomly assigned into one of 2 groups. The first group will receive a dose of up to 2mg of Pimozide per day and the second group will receive placebo (lactose tablets). Subjects will be assigned randomly (like by a flip of a coin) to receive either Pimozide 2 mg per day or placebo tablets. There will be a fifty-fifty chance of receiving Pimozide or placebo.
Participants will be on study medication up to 22 weeks, and on study up to 26 weeks. There are 8 clinic visits and 1 phone visit over the course of the Treatment Phase of the study. The second phase which is Observational, is optional with follow-up for up to 5 years from the end of the Treatment Phase.
100 people from several Canadian centres with ALS who have provided their consent will be randomly assigned into one of 2 groups. The first group will receive a dose of up to 2mg of Pimozide per day and the second group will receive placebo (lactose tablets). Subjects will be assigned randomly (like by a flip of a coin) to receive either Pimozide 2 mg per day or placebo tablets. There will be a fifty-fifty chance of receiving Pimozide or placebo.
Participants will be on study medication up to 22 weeks, and on study up to 26 weeks. There are 8 clinic visits and 1 phone visit over the course of the Treatment Phase of the study. The second phase which is Observational, is optional with follow-up for up to 5 years from the end of the Treatment Phase.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Registry-Based Clinical Trial of Pimozide in Patients With Neuromuscular Junction Transmission Dysfunction Due to ALS
NCT02463825
Amyotrophic Lateral Sclerosis (ALS)
UNKNOWN
PHASE2
Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis
NCT00706147
Amyotrophic Lateral Sclerosis
COMPLETED
PHASE2/PHASE3
A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS
NCT05357950
Amyotrophic Lateral Sclerosis
ALS
COMPLETED
PHASE2
Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS
NCT05349721
Amyotrophic Lateral Sclerosis
TERMINATED
PHASE2
A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS
NCT05279755
Amyotrophic Lateral Sclerosis
RECRUITING
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease is a neuromuscular disease that results in rapid decline in normal muscle function and tone leading to difficulties with mobility, eating, drinking, breathing, sleeping, and communicating. The disease is progressive and no cure currently exists. Most people diagnosed with ALS succumb within 3 to 5 years. Rilutek® (riluzole) has been approved as a treatment to slow progression of ALS, but is minimally effective with mean increase in survival of only a few months. Radicava® or Radicut® (edaravone) has recently been approved in Canada, USA, Japan and South Korea.
Muscular dysfunction present in people with ALS is caused by nerve breakdown and a dysfunction in the communication between the muscles and the nerves. The area where these communications occur is called the neuromuscular junction. Some recent studies have focused on using different medications to enhance communication at the neuromuscular junction with the goal of improving muscle function as a result. This approach is unproven but may help to slow the progression of the disease.
Pimozide is a medication that has been demonstrated to enhance communication at the neuromuscular junction in fish and mice. This study will look at whether Pimozide may help to slow the progression of ALS.
There are two parts to this study.
Treatment Phase: In the first part of this study, 100 people from several Canadian centres with ALS who have provided their consent will be randomly assigned into one of 2 groups. The first group will receive a dose of up to 2mg of Pimozide per day and the second group will receive placebo (lactose tablets). Subjects will be assigned randomly (like by a flip of a coin) to receive either Pimozide 2 mg per day or placebo tablets. There will be a fifty-fifty chance of receiving Pimozide or placebo.
Each Pimozide tablet contains 2 mg of Pimozide. The matching placebo tablets for this study will look exactly like the Pimozide tablets. Placebos are used in clinical trials to find out if the results observed in the study are due the drug being tested, or for other reasons.
Neither the subject nor their doctor will know which group a patient belongs to. However, if an emergency should arise, information about a treatment group will be shared with their doctor to ensure appropriate medical care. Participants will take their treatment once a day, every day for about 22 weeks. The total time in the study from the screen visit up until the last phone call communication is about 26 weeks.
Observational Phase: The second part of this study is optional. It is each subject's decision whether to participate only in the first part of this study, or in both parts of the study, or not at all. In the second part of this study, the Canadian Neuromuscular Disease Registry (CNDR) will collect data on overall ALS progression using the Revised ALS Functional Rating Scale (ALSFRS-R) and breathing using Vital Capacity data collected during breathing tests. This information will be collected from a subject medical record following each routine clinical appointment. Data will be collected at each routine clinic visit for up to 5 years from the end of the first part of the study. There will be no extra visits for this part of the study beyond routine ALS clinic visits.
The information collected during this part of the study will be used to compare the progression of ALS, after the clinical trial is completed, among the two treatment types (Placebo or 2 mg per day). By analyzing this information, the researchers conducting this study hope to determine if Pimozide may help to slow the progression of ALS. To participate in this part of the study consent must be provided to join the CNDR. A subject who hasn't already provided their CNDR consent, and wishes to participate in this part of the study will be given a CNDR consent form to review and sign in addition to this consent form. A subject already participating in the CNDR will just need to sign the main study consent form.
Muscular dysfunction present in people with ALS is caused by nerve breakdown and a dysfunction in the communication between the muscles and the nerves. The area where these communications occur is called the neuromuscular junction. Some recent studies have focused on using different medications to enhance communication at the neuromuscular junction with the goal of improving muscle function as a result. This approach is unproven but may help to slow the progression of the disease.
Pimozide is a medication that has been demonstrated to enhance communication at the neuromuscular junction in fish and mice. This study will look at whether Pimozide may help to slow the progression of ALS.
There are two parts to this study.
Treatment Phase: In the first part of this study, 100 people from several Canadian centres with ALS who have provided their consent will be randomly assigned into one of 2 groups. The first group will receive a dose of up to 2mg of Pimozide per day and the second group will receive placebo (lactose tablets). Subjects will be assigned randomly (like by a flip of a coin) to receive either Pimozide 2 mg per day or placebo tablets. There will be a fifty-fifty chance of receiving Pimozide or placebo.
Each Pimozide tablet contains 2 mg of Pimozide. The matching placebo tablets for this study will look exactly like the Pimozide tablets. Placebos are used in clinical trials to find out if the results observed in the study are due the drug being tested, or for other reasons.
Neither the subject nor their doctor will know which group a patient belongs to. However, if an emergency should arise, information about a treatment group will be shared with their doctor to ensure appropriate medical care. Participants will take their treatment once a day, every day for about 22 weeks. The total time in the study from the screen visit up until the last phone call communication is about 26 weeks.
Observational Phase: The second part of this study is optional. It is each subject's decision whether to participate only in the first part of this study, or in both parts of the study, or not at all. In the second part of this study, the Canadian Neuromuscular Disease Registry (CNDR) will collect data on overall ALS progression using the Revised ALS Functional Rating Scale (ALSFRS-R) and breathing using Vital Capacity data collected during breathing tests. This information will be collected from a subject medical record following each routine clinical appointment. Data will be collected at each routine clinic visit for up to 5 years from the end of the first part of the study. There will be no extra visits for this part of the study beyond routine ALS clinic visits.
The information collected during this part of the study will be used to compare the progression of ALS, after the clinical trial is completed, among the two treatment types (Placebo or 2 mg per day). By analyzing this information, the researchers conducting this study hope to determine if Pimozide may help to slow the progression of ALS. To participate in this part of the study consent must be provided to join the CNDR. A subject who hasn't already provided their CNDR consent, and wishes to participate in this part of the study will be given a CNDR consent form to review and sign in addition to this consent form. A subject already participating in the CNDR will just need to sign the main study consent form.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
ALS
Amyotrophic Lateral Sclerosis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1 Pimozide 2 mg (current) or 4 mg/day (study initiation)
Pimozide will be initiated at 2 mg once daily. The maximum dose will then be administered for a target period of 22 weeks.
Group Type
EXPERIMENTAL
Pimozide 2mg/day (current) or 4 mg/day (study initiation)
Intervention Type
DRUG
Pimozide 2mg tablets will be taken once daily.
Group 2 Placebo
Placebo tablets will be utilized and administered in an identical manner for subjects in Group 1
Group Type
PLACEBO_COMPARATOR
Placebo Oral Tablet
Intervention Type
DRUG
Identical matching placebo lactose tablets
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pimozide 2mg/day (current) or 4 mg/day (study initiation)
Pimozide 2mg tablets will be taken once daily.
Intervention Type
DRUG
Placebo Oral Tablet
Identical matching placebo lactose tablets
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Patients classified as having clinically definite, clinically probable, clinically probable (laboratory-supported) or clinically possible ALS according to the El-Escorial diagnostic criteria for ALS (see Appendix 2).
2. Able to comprehend and willing to sign Informed Consent Form (ICF).
3. Age 18 years of age or greater.
4. ALS Symptom onset of muscle weakness or speech impairment no more than 48 months prior to screen visit. Fasiculations should not be considered.
5. Slow Vital Capacity (SVC) greater than or equal to 50% predicted for sex, age and height at screen.
6. Has the ability to swallow tablets/capsules whole at study entry.
7. Subject with clinical laboratory findings within the normal range or, if outside the normal range, determined by the Investigator at the Screening visit to be not clinically significant.
8. If the subject is taking Riluzole the dose must be stable for 30 days prior to the randomization visit. Riluzole cannot be initiated during the study.
9. If the subject is receiving Edaravone therapy, the dose must be stable for at least 1 cycle of infusion treatments before the randomization visit.
2. Able to comprehend and willing to sign Informed Consent Form (ICF).
3. Age 18 years of age or greater.
4. ALS Symptom onset of muscle weakness or speech impairment no more than 48 months prior to screen visit. Fasiculations should not be considered.
5. Slow Vital Capacity (SVC) greater than or equal to 50% predicted for sex, age and height at screen.
6. Has the ability to swallow tablets/capsules whole at study entry.
7. Subject with clinical laboratory findings within the normal range or, if outside the normal range, determined by the Investigator at the Screening visit to be not clinically significant.
8. If the subject is taking Riluzole the dose must be stable for 30 days prior to the randomization visit. Riluzole cannot be initiated during the study.
9. If the subject is receiving Edaravone therapy, the dose must be stable for at least 1 cycle of infusion treatments before the randomization visit.
Exclusion Criteria
1. History of laryngeal spasm, dystonia, or akathisia.
2. Diagnosis of ongoing symptomatic Restless Leg Syndrome or undergoing current treatment for Restless Leg Syndrome. If subject has symptoms that resemble or have the potential to be Restless Leg Syndrome, then further investigation should be undertaken to confirm or rule out diagnosis of Restless Leg Syndrome.
3. Any history of moderate or severe traumatic brain injury as defined by a Glasgow Coma Scale Score of less than 13/15 at any time point following a head injury without sedation or other reason for a decreased level of consciousness.
4. History of neuroleptic malignant syndrome.
5. History of hypersensitivity or serious adverse reaction(s) to a neuroleptic medication.
6. History of hyponatremia \< 130 mmol/L
7. Subject with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) value \>3.0 times the upper limit of normal at the Screening visit.
8. Current heparin or warfarin use.
9. History of hepatic and/or renal impairment that may affect pimozide metabolism
10. History of current pregnancy, or breastfeeding women, or women planning to become pregnant. Female subjects of childbearing potential (sexually mature female who has not undergone a hysterectomy or who has not been post-menopausal for 12 consecutive months), must practise effective contraception during the study and be willing and able to continue contraception until the Follow-up phone visit after discontinuing study medication. Abstinence can be considered an acceptable method of contraception at the discretion of the investigator.
11. Current antipsychotic use
12. Presence of central nervous system depression, comatose states, liver disorders, renal insufficiency, and blood dyscrasias
13. Presence of Parkinson's syndrome
14. Presence of major depressive disorders as determined by site Investigator.
15. History of clinically significant ECG abnormalities at screen visit, including QTc\>500ms.
16. History of congenital long QT syndrome or with a family history of this syndrome and in patients with a history of cardiac arrhythmias or Torsade de Pointes.
17. Presence of acquired long QT interval, and/or concomitant use of drugs known to prolong the QT interval (TCAs, opioids such as methodone, quinolone antibiotics (ciprofloxacin), antimalarials (quinine), Detrol, azole antifungals, Class 1A, III and 1C antiarrhythmics, and macrolide antibiotics.
18. Presence of clinically significant bradycardia (heart rate \< 50 beats per minute)
19. Presence of hypokalemia or hypomagnesemia.
20. The concomitant use of CYP 3A4-inhibiting drugs such as azole antimycotics, antiviral protease inhibitors, macrolide antibiotics and nefazodone.
21. The concomitant use of CYP 2D6-inhibiting drugs such as quinidine is also contraindicated.
22. Concomitant use of serotonin reuptake inhibitors, such as, sertraline, paroxetine, citalopram and escitalopram.\*
23. Has taken any compound under current or known future study as a potential therapy (including Withania) for ALS less than 30 days prior to dosing OR history of exposure to stem cell therapy for treatment of ALS at any time.
24. Current Neurological impairment due to a condition other than ALS:
1. Subject in whom causes of neuromuscular weakness other than ALS have not been excluded.
2. Subject with a diagnosis of other neurodegenerative diseases (e.g., Parkinson's disease, Frontotemporal dementia, Alzheimer's disease, etc.)
25. Use of non-invasive ventilation (BiPAP or CPAP) prior to Baseline visit at any time.
26. Cognitive impairment as determined by the Site Investigator, subject must not have an impaired ability to provide informed consent and must be able to understand study processes and comply with study procedures.
27. Extrapyramidal Symptom Rating Scale (ESRS) Parkinsonism score of 2 on 2 items or a score \> 3 on 1 item; OR Dystonia score of \>3 on at least 1 item or a score of 2 on 2 items; OR Tardive Dyskinesia score of \>3 on at least 1 item or a score of 2 on 2 items. Do not consider scores greater than 3 for Tremor in any region if due to Benign Essential, Exaggerated, or Physiological Tremor.
28. The concomitant use of SSRIs and tricyclic antidepressants (e.g. amitriptyline, amoxaprine, desipramine, doxepin, imipramine, nortriptyline, protripyline, trimipramine) - and Tolterodine (Detrol) CYP2D6 inhibitor.
* Prohibited medications such as tricyclic antidepressants, antimalarials, and serotonin reuptake inhibitors,(ie sertraline, paroxetine, citalopram, fluoxetine, vilazodone and escitalopram) may be weaned to full discontinuation at the screening visit after consent has been signed (no study procedures including adjustments to medication may occur until informed consent has been provided).
2. Diagnosis of ongoing symptomatic Restless Leg Syndrome or undergoing current treatment for Restless Leg Syndrome. If subject has symptoms that resemble or have the potential to be Restless Leg Syndrome, then further investigation should be undertaken to confirm or rule out diagnosis of Restless Leg Syndrome.
3. Any history of moderate or severe traumatic brain injury as defined by a Glasgow Coma Scale Score of less than 13/15 at any time point following a head injury without sedation or other reason for a decreased level of consciousness.
4. History of neuroleptic malignant syndrome.
5. History of hypersensitivity or serious adverse reaction(s) to a neuroleptic medication.
6. History of hyponatremia \< 130 mmol/L
7. Subject with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) value \>3.0 times the upper limit of normal at the Screening visit.
8. Current heparin or warfarin use.
9. History of hepatic and/or renal impairment that may affect pimozide metabolism
10. History of current pregnancy, or breastfeeding women, or women planning to become pregnant. Female subjects of childbearing potential (sexually mature female who has not undergone a hysterectomy or who has not been post-menopausal for 12 consecutive months), must practise effective contraception during the study and be willing and able to continue contraception until the Follow-up phone visit after discontinuing study medication. Abstinence can be considered an acceptable method of contraception at the discretion of the investigator.
11. Current antipsychotic use
12. Presence of central nervous system depression, comatose states, liver disorders, renal insufficiency, and blood dyscrasias
13. Presence of Parkinson's syndrome
14. Presence of major depressive disorders as determined by site Investigator.
15. History of clinically significant ECG abnormalities at screen visit, including QTc\>500ms.
16. History of congenital long QT syndrome or with a family history of this syndrome and in patients with a history of cardiac arrhythmias or Torsade de Pointes.
17. Presence of acquired long QT interval, and/or concomitant use of drugs known to prolong the QT interval (TCAs, opioids such as methodone, quinolone antibiotics (ciprofloxacin), antimalarials (quinine), Detrol, azole antifungals, Class 1A, III and 1C antiarrhythmics, and macrolide antibiotics.
18. Presence of clinically significant bradycardia (heart rate \< 50 beats per minute)
19. Presence of hypokalemia or hypomagnesemia.
20. The concomitant use of CYP 3A4-inhibiting drugs such as azole antimycotics, antiviral protease inhibitors, macrolide antibiotics and nefazodone.
21. The concomitant use of CYP 2D6-inhibiting drugs such as quinidine is also contraindicated.
22. Concomitant use of serotonin reuptake inhibitors, such as, sertraline, paroxetine, citalopram and escitalopram.\*
23. Has taken any compound under current or known future study as a potential therapy (including Withania) for ALS less than 30 days prior to dosing OR history of exposure to stem cell therapy for treatment of ALS at any time.
24. Current Neurological impairment due to a condition other than ALS:
1. Subject in whom causes of neuromuscular weakness other than ALS have not been excluded.
2. Subject with a diagnosis of other neurodegenerative diseases (e.g., Parkinson's disease, Frontotemporal dementia, Alzheimer's disease, etc.)
25. Use of non-invasive ventilation (BiPAP or CPAP) prior to Baseline visit at any time.
26. Cognitive impairment as determined by the Site Investigator, subject must not have an impaired ability to provide informed consent and must be able to understand study processes and comply with study procedures.
27. Extrapyramidal Symptom Rating Scale (ESRS) Parkinsonism score of 2 on 2 items or a score \> 3 on 1 item; OR Dystonia score of \>3 on at least 1 item or a score of 2 on 2 items; OR Tardive Dyskinesia score of \>3 on at least 1 item or a score of 2 on 2 items. Do not consider scores greater than 3 for Tremor in any region if due to Benign Essential, Exaggerated, or Physiological Tremor.
28. The concomitant use of SSRIs and tricyclic antidepressants (e.g. amitriptyline, amoxaprine, desipramine, doxepin, imipramine, nortriptyline, protripyline, trimipramine) - and Tolterodine (Detrol) CYP2D6 inhibitor.
* Prohibited medications such as tricyclic antidepressants, antimalarials, and serotonin reuptake inhibitors,(ie sertraline, paroxetine, citalopram, fluoxetine, vilazodone and escitalopram) may be weaned to full discontinuation at the screening visit after consent has been signed (no study procedures including adjustments to medication may occur until informed consent has been provided).
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ALS Canada
UNKNOWN
Sponsor Role
collaborator
Brain Canada
OTHER
Sponsor Role
collaborator
University of Calgary
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
DR. LAWRENCE KORNGUT
M.D. Director Calgary ALS and Motor Neuron Disease Clinic
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lawrence Korngut, M.D.
Role: PRINCIPAL_INVESTIGATOR
University of Calgary and Alberta Health Services
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dr. Lawrence Korngut -South Health Campus
Calgary, Alberta, Canada
Site Status
RECRUITING
Dr. Wendy Johnston - University of Alberta
Edmonton, Alberta, Canada
Site Status
RECRUITING
Dr. Colleen O'Connell - Stan Cassidy Centre for Rehabilitation
Fredericton, New Brunswick, Canada
Site Status
RECRUITING
Dr. John Turnbull McMaster University/Hamilton Health Services
Hamilton, Ontario, Canada
Site Status
RECRUITING
Dr. Christen Shoesmith - London Health Sciences Centre
London, Ontario, Canada
Site Status
RECRUITING
Dr. Ariel Breiner -Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Site Status
RECRUITING
Dr. Lorne Zinman Sunnybrook Research Institute
Toronto, Ontario, Canada
Site Status
RECRUITING
Dr. Sandrine Larue - Reserche Sepmus Inc.
Greenfield Park, Quebec, Canada
Site Status
RECRUITING
Dr. Genevieve Matte
Montreal, Quebec, Canada
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Canada
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pimozide2_ALS-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT07082192
NOT_YET_RECRUITING
PHASE2/PHASE3
Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation
NCT02794857
COMPLETED
PHASE2
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
NCT06665165
RECRUITING
PHASE1
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
NCT03127267
RECRUITING
PHASE3
Combination Therapy in Amyotrophic Lateral Sclerosis (ALS)
NCT00919555
COMPLETED
PHASE1/PHASE2
A Trial of Tocilizumab in ALS Subjects
NCT02469896
COMPLETED
PHASE2
Enoxacin for Amyotrophic Lateral Sclerosis (ALS)
NCT04840823
COMPLETED
PHASE1/PHASE2
Clinical Trial of Ezogabine (Retigabine) in ALS Subjects
NCT02450552
COMPLETED
PHASE2
Gilenya in Amyotrophic Lateral Sclerosis (ALS)
NCT01786174
COMPLETED
PHASE2
Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)
NCT01091142
COMPLETED
PHASE1
Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
NCT01753076
COMPLETED
PHASE2
Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
NCT01492686
COMPLETED
PHASE3
Trial of Early Noninvasive Ventilation for Amyotrophic Lateral Sclerosis (ALS)
NCT00580593
COMPLETED
PHASE1
Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)
NCT01884571
COMPLETED
PHASE2
A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)
NCT03020797
TERMINATED
NA
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
NCT02496767
COMPLETED
PHASE3
Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial
NCT00035815
COMPLETED
PHASE3
A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS
NCT01999803
TERMINATED
PHASE1
A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT03160898
COMPLETED
PHASE2
Study of COYA 302 for the Treatment of ALS
NCT07161999
RECRUITING
PHASE2
Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III
NCT00415519
COMPLETED
PHASE3
Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol)
NCT05508074
COMPLETED
PHASE2
Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
NCT00330681
COMPLETED
PHASE3
Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT02460679
COMPLETED
PHASE2
Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS
NCT03505021
COMPLETED
PHASE3